Assuntos
Anticorpos/análise , Anticoagulantes/efeitos adversos , Antitrombinas/uso terapêutico , Benzimidazóis/uso terapêutico , Sulfatos de Condroitina/uso terapêutico , Dermatan Sulfato/uso terapêutico , Fibrinolíticos/uso terapêutico , Heparina/efeitos adversos , Heparina/imunologia , Heparitina Sulfato/uso terapêutico , Hirudinas , Fragmentos de Peptídeos/uso terapêutico , Ácidos Pipecólicos/uso terapêutico , Inibidores da Agregação Plaquetária/uso terapêutico , Polissacarídeos/uso terapêutico , Piridinas/uso terapêutico , Proteínas Recombinantes/uso terapêutico , Trombina/antagonistas & inibidores , Trombocitopenia/induzido quimicamente , Trombocitopenia/terapiaAssuntos
Anticoagulantes/uso terapêutico , Antitrombinas/uso terapêutico , Benzimidazóis/uso terapêutico , Humanos , Morfolinas/uso terapêutico , Ácidos Pipecólicos/uso terapêutico , Pirazóis/uso terapêutico , Piridonas/uso terapêutico , Tiofenos/uso terapêutico , Tromboembolia Venosa/prevenção & controle , beta-Alanina/análogos & derivados , beta-Alanina/uso terapêuticoRESUMO
The concept of neuroprotection relies on the principle that delayed neuronal injury occurs after ischemia. The phenomenon of the "ischemic cascade" has been described, and each step along this cascade provides a target for therapeutic intervention. A wide variety of drugs have been studied in humans. Ten classes of neuroprotective agents have reached phase III efficacy trials but have shown mixed results. They included calcium channel antagonists, NMDA receptor antagonists, lubeluzole, CDP-choline, the free radical scavenger tirilazad and ebselen, enlimomab, GABA agonist clomethiazole, the sodium channel antagonist fosphenytoin, magnesium, glycine site antagonist GV150526 and piracetam. Furthermore, the mechanisms that underlie the development of focal ischemic injury continue to be discovered, opening new therapeutic perspective for neuroprotection that might clinically be applicable in the future.